Chlorthalidone for Hypertension in Advanced CKD


AFŞAR B., Kanbay M., ELSÜRER AFŞAR R.

NEW ENGLAND JOURNAL OF MEDICINE, vol.386, no.14, pp.1382-1384, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Letter
  • Volume: 386 Issue: 14
  • Publication Date: 2022
  • Doi Number: 10.1056/nejmc2201160
  • Journal Name: NEW ENGLAND JOURNAL OF MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
  • Page Numbers: pp.1382-1384
  • Süleyman Demirel University Affiliated: Yes

Abstract

To the Editor: Agarwal and colleagues (Dec. 30 issue)(1) report the findings from a trial evaluating the use of chlorthalidone as an antihypertensive agent in patients with advanced chronic kidney disease (CKD) and poorly controlled hypertension. Although the findings show the potential of chlorthalidone as a valuable add-on therapy for poorly controlled hypertension, the article lacks the necessary discussion of common and potentially harmful side effects of thiazide diuretics. In a recent cross-sectional analysis conducted in Switzerland, we showed that approximately one in five patients receiving a thiazide diuretic presented with hyponatremia or hypokalemia.(2) Chlorthalidone was the thiazide diuretic with . . .